MIT Research Offers New Hope For Alzheimer's Patients, Cocktail Of
Dietary Supplements, Now In Human Clinical Trials
This Article
Also Appears In
Neurology / NeuroscienceNutrition/Agriculture

Main Category: Alzheimer's News
Article Date: 28 Apr 2006 - 0:00am (PDT)

MIT brain researchers have developed a "cocktail" of dietary
supplements, now in human clinical trials, that holds promise for the
treatment of Alzheimer's disease.

For years, doctors have encouraged people to consume foods such as fish
that are rich in omega-3 fatty acids because they appear to improve
memory and other brain functions.

The MIT research suggests that a cocktail treatment of omega-3 fatty
acids and two other compounds normally present in the blood, could
delay the cognitive decline seen in Alzheimer's disease, which afflicts
an estimated 4 million to 5 million Americans.

"It's been enormously frustrating to have so little to offer people
that have (Alzheimer's) disease," said Richard Wurtman, the Cecil H.
Green Distinguished Professor of Neuropharmacology at MIT, who led the
research team. The study appears in the May 9 issue of Brain Research.

Wurtman will present the research at the International Academy of
Nutrition and Aging 2006 Symposium on Nutrition and Alzheimer's
Disease/Cognitive Decline in Chicago on Tuesday, May 2.

The three compounds in the treatment cocktail - omega-3 fatty acids,
uridine and choline - are all needed by brain neurons to make
phospholipids, the primary component of cell membranes.

After adding those supplements to the diets of gerbils, the researchers
observed a dramatic increase in the amount of membranes that form brain
cell synapses, where messages between cells are relayed. Damage in
brain synapses is believed to cause the dementia that characterizes
Alzheimer's disease.

If the successful results obtained in gerbils can be duplicated in the
ongoing human trials, the new treatment could offer perhaps not a cure
but a long-term Alzheimer's treatment similar to what L-dopa, a
dopamine precursor, does for Parkinson's patients, said Wurtman, a
professor in the Department of Brain and Cognitive Sciences.

"It doesn't cure Parkinson's, but what it does do is to help replace
something that's missing. It's not permanent, but it has had an
enormous impact on people who have Parkinson's," he said.

The new potential treatment offers a different approach from the
traditional tactic of targeting the amyloid plaques and tangles that
develop in the brains of Alzheimer's patients. Until recently, most
researchers believed these plaques and tangles caused the cognitive
decline. But the failure of this hypothesis to lead to an effective
treatment for Alzheimer's disease has caused some scientists to
theorize that, though the plaques and tangles are always associated
with the disease, they may not be the main cause of the dementia, nor
the best target for treating it.

Instead, the new research focuses on brain synapses, where
neurotransmitters such as dopamine, acetylcholine, serotonin and
glutamate carry messages from presynaptic neurons to receptors in the
membranes of postsynaptic neurons. In Alzheimer's patients, synapses in
the cortex and hippocampus, which are involved in learning and memory,
are damaged.

After the dietary supplements were given, the researchers detected a
large increase in the levels of specific brain proteins known to be
concentrated within synapses, indicating that more synaptic membranes
had formed, Wurtman said. Synaptic membrane protein levels rose if the
gerbils were given either omega-3 fatty acids or uridine plus choline.
However, the most dramatic upsurge was observed in gerbils fed all
three compounds.

"To my knowledge, this is the first concrete explanation for the
behavioral effects of taking omega-3 fatty acids," said Wurtman.

Choline can be found in meats, nuts and eggs, and omega-3 fatty acids
are found in a variety of sources, including fish, eggs, flaxseed and
meat from grass-fed animals. Uridine, which is found in RNA and
produced by the liver and kidney, is not obtained from the diet.
However, uridine is found in human breast milk, which is a good
indication that supplementary uridine is safe for humans to consume,
Wurtman said.

Recent studies by the researchers at MIT, and by scientists at
Cambridge University in England, showed that either uridine or omega-3
fatty acids can promote the growth of neurites, which are small
outgrowths of neuronal cell membranes. That further supports the
hypothesis that omega-3 fatty acids increase synaptic membrane
formation, said Wurtman.

Alzheimer's patients in the clinical trials, which will involve
multiple medical centers, are being given a drink that contains the
compounds under study, or a taste-matched placebo.

"If it works as well on the brains of people with Alzheimer's disease
as it does in laboratory animals, I think there will be a lot of
interest," Wurtman said.

Other authors on the paper are Ismail Ulus, Mehmet Cansev, Carol
Watkins, Lei Wang and George Marzloff of MIT's Department of Brain and
Cognitive Sciences. Ulus and Cansev also work at the Uludag University
School of Medicine in Turkey.

The research was supported by the National Institutes of Health, the
Center for Brain Sciences and Metabolism Charitable Trust and the
Turkish Academy of Sciences.

http://web.mit.edu/newsoffice/www

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com

Man Is A Herbivore!
http://pages.ivillage.com/ironjustice/manisaherbivore

DEAD PEOPLE WALKING
http://pages.ivillage.com/ironjustice/deadpeoplewalking